Who is Leena Tewari? Owner of India's costliest flats worth over Rs 700 crore, spanning 22,572 sq ft in Worli
Leena Tewari
, the chairperson of Mumbai-based
USV Pharmaceuticals
, recently captured public attention for buying India's most expensive residential property—a pair of sea-facing luxury duplex apartments in Worli, Mumbai, for a staggering Rs 639 crore. She also paid Rs 63.9 crore stamp duty and GST. That's nearly Rs 703 crore in total.
The landmark deal
This landmark deal, reported by The Economic Times on May 28, set a new record in the Indian real estate market with a price exceeding Rs 2.83 lakh per sq ft on a carpet basis, covering 22,572 sq ft across the 32nd to 35th floors of a premium 40-storey tower overlooking the Arabian Sea.
She paid over Rs 63.9 crore towards stamp duty and the Goods & Services Tax alone for the registration of the transaction. After accounting for these charges, she has paid a total of nearly Rs 703 crore for the deals.
Though widely known among patients for USV's flagship medicines such as
Glycomet
(for diabetes), Ecosprin (a blood thinner), and Roseday (for cholesterol), Leena Tewari herself maintains a notably low profile.
Leena Tewari's net worth
Forbes estimates her net worth at $3.9 billion, placing her among India's richest women. Despite her immense wealth, she has kept a discreet presence in business and social circles.
Live Events
Tewari is also a close friend of
Nita Ambani
, a prominent figure in Indian business and philanthropy.
USV: Leena Tewari's family-run company
Under Tewari's leadership, USV remains a family-run company, steadfastly resisting pressures to sell out, bring in private equity, or go public. USV reported revenues of Rs 4,840 crore in FY24, driven by its stronghold on the Indian pharmaceutical market, especially in the diabetes segment.
Glycomet ranks as the second-leading anti-diabetes drug in India, just behind GSK's Augmentin. The company's other brands like Ecosprin and Roseday also command significant market shares.
Looking ahead, USV faces growing competition from new generation diabetes drugs. To maintain its edge, the company is focusing on expanding its insulin portfolio in India and developing generic versions of blockbuster weight-loss drugs such as Ozempic and Wegovy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
26 minutes ago
- NDTV
Honda Cars India's Total Wholesale In May'25 Stood At 5,985 Units
Honda Cars India Ltd. (HCIL), registered total sales of 5,985 units in May'25. Domestic sales of the company stood at 3,950 units and exports at 2,035 units. Sharing thoughts on the sales performance, Mr. Kunal Behl, Vice President, Marketing & Sales, Honda Cars India Ltd. said, "In view of the prevailing market conditions and subdued consumer sentiment, we continued to strategically moderate our dispatches in May to maintain optimal inventory levels across our network, while remaining optimistic about improved retail performance in the coming months supported by forecasts of a better monsoon." In the corresponding month last year, the Japanese marque retailed 4,822 units in the Indian market, while the export figures stood at 6,521 units. Besides, the new helmsman, Takashi Nakajima, who recently took over as the president and CEO of the company from Takuya Tsumura, made a slew of announcements at an informal event in Delhi. One of the highlights was the confirmation of the launch of a new battery electric vehicle (BEV) in the next fiscal year. It will not be based on the Honda Elevate, as speculated earlier, but instead it will be an EV made specifically for the Indian market. Honda hasn't made it clear whether the new EV will be an SUV or a sedan, but sources suggest that it is likely to be SUV, that could go up against the likes of the Maruti Suzuki e-Vitara, Hyundai Creta EV, Tata Curvv EV and so on. The company believes in having a different brand strategy for ICE and electric vehicles, unlike some other brands which opt for the same/similar branding. Honda is also silently working on its charging infrastructure, so that when the new EV arrives, the support network will be ready.
Business Standard
27 minutes ago
- Business Standard
Aegis Vopak Terminals slips on debut
Shares of Aegis Vopak Terminals were currently trading at Rs 228.95 at 10:14 IST on the BSE, representing a discount of 2.57% compared with the issue price of Rs 235. The scrip was listed at Rs 220, exhibiting a discount of 6.38% to the issue price. So far, the stock has hit a high of 235.75 and a low of 220. On the BSE, over 6.57 lakh shares of the company were traded in the counter so far. The initial public offer of Aegis Vopak Terminals was subscribed 2.09 times. The issue opened for bidding on 26 May 2025 and it closed on 28 May 2025. The price band of the IPO is fixed between Rs 223 and 235 per share. The offer comprised a fresh issue of up to 119,148,936 equity shares at the upper price band of Rs 235 and 125,560,538 equity shares at the lower price band of Rs 223, aggregating to Rs 2,800 crore. The company will use the IPO proceeds to repay borrowings worth Rs 2,015.95 crore, fund Rs 671.3 crore towards acquiring a cryogenic LPG terminal at Mangalore, and for general corporate purposes. As of 31 March 2025, total borrowings stood at Rs 2,474.17 crore. The Mangalore terminal, with a total capex of Rs 968 crore, is expected to commence operations by June 2025. The project is being developed by Sea Lord Containers, a wholly owned subsidiary of Aegis Logistics and part of the promoter group. Ahead of the IPO, Aegis Vopak Terminals on Friday, 23 May 2025, raised Rs 1,259.99 crore from anchor investors. The board allotted 53,617,021 shares at Rs 235 each to 32 anchor investors. Aegis Vopak Terminals is India's largest third-party tank storage operator for LPG and liquid products, with a total capacity of 1.5 million cubic meters for liquids and 70,800 tonnes for LPG as of 31 December 2024. The company accounts for approximately 11.5% of Indias total LPG static storage capacity and 25.5% of third-party liquid storage capacity. Aegis Vopak is a joint venture between Aegis Logistics (50.1%) and Vopak India BV (47.4%), part of Dutch-based Royal Vopak, a global leader in tank storage with 77 terminals in 23 countries. The company is expanding LPG storage capacity to 200,800 tonnes by FY26 and recently added 101,900 cubic meters of liquid storage at its JNPA terminal in Navi Mumbai. The firm reported a consolidated net profit of Rs 85.8910 crore and total income of Rs 464.18 crore for the nine months ended on 31 December 2024.
Business Standard
27 minutes ago
- Business Standard
Cipla's Bengaluru facility gets one USFDA observation
Cipla announced that the United States Food and Drug Administration (USFDA) has concluded a current Good Manufacturing Practices (cGMP) inspection at its manufacturing facility in Bommasandra, Bengaluru. According to a regulatory filing, the inspection was carried out from 26 May 2025 to 30 May 2025. At the conclusion of the inspection, the USFDA issued one observation in Form 483. The company stated that it will work closely with the USFDA and remains committed to addressing the observation comprehensively within the stipulated timeframe. In Q4 FY25, Cipla reported a 30.1% year-on-year increase in consolidated net profit to Rs 1,222 crore, while total income rose 9.2% to Rs 6,730 crore. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets. The scrip shed 0.19% to currently trade at Rs 1,462 on the BSE.
